Identification

Name
Vinorelbine
Accession Number
DB00361  (APRD00101)
Type
Small Molecule
Groups
Approved, Investigational
Description

Vinorelbine (Navelbine®) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. [Wikipedia]

Structure
Thumb
Synonyms
  • 5'-Noranhydrovinblastine
  • Nor-5'-anhydrovinblastine
  • Vinorelbin
  • Vinorelbina
  • Vinorelbine
  • Vinorelbinum
External IDs
KW 2307 base / KW-2307 / UNII-253GQW851Q / UNII-Q6C979R91Y
Product Ingredients
IngredientUNIICASInChI Key
Vinorelbine DitartrateNot AvailableNot AvailableNot applicable
Vinorelbine Tartrate253GQW851Q125317-39-7CILBMBUYJCWATM-KRQCOKQWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aj-vinorelbineSolution10 mgIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
NavelbineInjection10 mg/mLIntravenousPierre Fabre Laboratories2005-11-15Not applicableUs
NavelbineSolution10 mgIntravenousPierre Fabre Pharma Canada Inc1994-12-312012-10-01Canada
Vinorelbine InjectionSolution10 mgIntravenousFresenius Kabi2009-03-31Not applicableCanada
Vinorelbine Injection, USPSolution10 mgIntravenousGeneric Medical Partners Inc2017-08-01Not applicableCanada
Vinorelbine Injection, USPSolution10 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Vinorelbine Tartrate for InjectionSolution10 mgIntravenousTeva2007-05-09Not applicableCanada
Vinorelbine Tartrate for InjectionSolution10 mgIntravenousPfizer2004-12-22Not applicableCanada
Vinorelbine Tartrate Injection USPSolution10 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VinorelbineInjection, solution10 mg/mLIntravenousMylan Institutional2012-09-012017-09-29Us
VinorelbineInjection, solution10 mg/mLIntravenousMylan Institutional2012-09-012017-09-29Us
VinorelbineInjection, solution10 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-09-012017-09-29Us
VinorelbineInjection, solution10 mg/mLIntravenousSagent Pharmaceuticals2014-09-15Not applicableUs
VinorelbineInjection, solution10 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-09-012017-09-29Us
VinorelbineInjection, solution10 mg/mLIntravenousHospira, Inc.2005-06-02Not applicableUs
VinorelbineInjection, solution10 mg/mLIntravenousMylan Institutional2012-09-012017-09-28Us
VinorelbineInjection, solution, concentrate10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2003-03-01Not applicableUs
VinorelbineInjection, solution10 mg/mLIntravenousActavis Pharma Company2009-09-14Not applicableUs
VinorelbineInjection, solution10 mg/mLIntravenousMylan Institutional2012-09-012017-09-28Us
International/Other Brands
Bendarelbin (Bendalis) / Eberelbin (Ebewe) / Eunexon (AC Farma) / Eurovinorelbin (Lapharm) / Filcrin (Filaxis) / Navelbin (Pierre Fabre) / Navildez (Cryopharma) / Navin (Cancernova) / Navirel (medac) / Neocitec (Sandoz) / Renovel (Mustafa Nevzat) / Riborelbin (Ribosepharm) / Vilne (Dosa) / Vinelbine (GP-Pharm) / Vinorayne (Hospira) / Vinorel (Eriochem) / Vinorgen (Bago) / Vinotel (Fresenius) / Zinavin (Novamed)
Categories
UNII
Q6C979R91Y
CAS number
71486-22-1
Weight
Average: 778.9323
Monoisotopic: 778.394164724
Chemical Formula
C45H54N4O8
InChI Key
GBABOYUKABKIAF-GHYRFKGUSA-N
InChI
InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45+/m0/s1
IUPAC Name
methyl (1R,9R,10R,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][[email protected]@]12N(C)C3=CC(OC)=C(C=C3[[email protected]@]11CCN3CC=C[[email protected]@](CC)([[email protected]@H](OC(C)=O)[[email protected]@]2(O)C(=O)OC)[[email protected]@]13[H])[[email protected]]1(C[[email protected]@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC

Pharmacology

Indication

For the treatment of non-small-cell lung carcinoma.

Structured Indications
Pharmacodynamics

Vinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Mechanism of action

The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

TargetActionsOrganism
ATubulin beta chain
inhibitor
Human
Absorption
Not Available
Volume of distribution
  • 25.4 to 40.1 L/kg
Protein binding

~27%

Metabolism
Not Available
Route of elimination

Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces after intravenous administration to humans.

Half life

27.7-43.6 hours

Clearance
  • 0.97 - 1.26 L/hr/kg
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Vinorelbine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Vinorelbine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Vinorelbine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Vinorelbine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vinorelbine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Vinorelbine.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Vinorelbine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Vinorelbine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Vinorelbine.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Vinorelbine.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Vinorelbine.Approved, Investigational
AmiodaroneThe metabolism of Vinorelbine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Vinorelbine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Vinorelbine.Approved
AprepitantThe serum concentration of Vinorelbine can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Vinorelbine.Approved, Investigational
ArtemetherThe metabolism of Vinorelbine can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Vinorelbine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Vinorelbine.Approved
AtomoxetineThe metabolism of Vinorelbine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Vinorelbine.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Vinorelbine.Investigational
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Vinorelbine.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
BetaxololThe metabolism of Vinorelbine can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Vinorelbine.Approved, Investigational
BoceprevirThe metabolism of Vinorelbine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Vinorelbine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vinorelbine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Vinorelbine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vinorelbine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Vinorelbine.Approved, Investigational
BupropionThe metabolism of Vinorelbine can be decreased when combined with Bupropion.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinorelbine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Vinorelbine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Vinorelbine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Vinorelbine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Vinorelbine.Approved
CarbamazepineThe metabolism of Vinorelbine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Vinorelbine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Vinorelbine.Approved
CelecoxibThe metabolism of Vinorelbine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Vinorelbine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Vinorelbine.Withdrawn
ChloroquineThe metabolism of Vinorelbine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Vinorelbine.Approved, Vet Approved
CholecalciferolThe metabolism of Vinorelbine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Vinorelbine.Approved
CinacalcetThe metabolism of Vinorelbine can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Vinorelbine.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Vinorelbine.Approved
ClarithromycinThe metabolism of Vinorelbine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Vinorelbine can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Vinorelbine.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Vinorelbine.Approved, Investigational
ClomipramineThe metabolism of Vinorelbine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Vinorelbine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Vinorelbine.Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vinorelbine.Approved
ClotrimazoleThe metabolism of Vinorelbine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Clozapine.Approved
CobicistatThe serum concentration of Vinorelbine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Vinorelbine.Approved
CocaineThe metabolism of Vinorelbine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Vinorelbine.Approved
ConivaptanThe serum concentration of Vinorelbine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Vinorelbine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Vinorelbine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vinorelbine.Approved
CrizotinibThe metabolism of Vinorelbine can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vinorelbine.Approved, Investigational
CyclosporineThe metabolism of Vinorelbine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Vinorelbine.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinorelbine.Approved
DabrafenibThe serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Vinorelbine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Vinorelbine.Approved
DarifenacinThe metabolism of Vinorelbine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Vinorelbine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Vinorelbine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Vinorelbine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Vinorelbine.Approved
DeferasiroxThe serum concentration of Vinorelbine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Vinorelbine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vinorelbine.Approved
DesipramineThe metabolism of Vinorelbine can be decreased when combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vinorelbine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Vinorelbine.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Vinorelbine.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vinorelbine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vinorelbine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Vinorelbine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Vinorelbine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Vinorelbine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Vinorelbine.Experimental
DihydroergotamineThe metabolism of Vinorelbine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Vinorelbine.Illicit
DiltiazemThe metabolism of Vinorelbine can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Vinorelbine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Vinorelbine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Vinorelbine.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Vinorelbine can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vinorelbine.Approved, Investigational
DoxycyclineThe metabolism of Vinorelbine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Vinorelbine can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Vinorelbine can be decreased when combined with Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vinorelbine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Vinorelbine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Vinorelbine.Approved, Investigational
EliglustatThe metabolism of Vinorelbine can be decreased when combined with Eliglustat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Vinorelbine.Approved
EnzalutamideThe serum concentration of Vinorelbine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Vinorelbine.Approved, Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Vinorelbine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Vinorelbine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Vinorelbine.Approved, Investigational
ErythromycinThe serum concentration of Vinorelbine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Vinorelbine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Vinorelbine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Vinorelbine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Vinorelbine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Vinorelbine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vinorelbine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Vinorelbine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinorelbine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Vinorelbine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Vinorelbine.Approved
FingolimodVinorelbine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe metabolism of Vinorelbine can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Vinorelbine can be decreased when combined with Fluoxetine.Approved, Vet Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Vinorelbine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Vinorelbine.Approved
FluvoxamineThe metabolism of Vinorelbine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vinorelbine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vinorelbine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Vinorelbine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Vinorelbine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Vinorelbine.Investigational
GefitinibGefitinib may increase the neutropenic activities of Vinorelbine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Vinorelbine.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vinorelbine.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Vinorelbine.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Vinorelbine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Vinorelbine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Vinorelbine.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Vinorelbine.Approved
IdelalisibThe serum concentration of Vinorelbine can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Vinorelbine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Vinorelbine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Vinorelbine.Approved
IndinavirThe metabolism of Vinorelbine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Vinorelbine.Approved, Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Vinorelbine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Vinorelbine.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vinorelbine.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Vinorelbine.Approved, Investigational
IsavuconazoniumThe metabolism of Vinorelbine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Vinorelbine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Vinorelbine can be decreased when combined with Isradipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vinorelbine.Approved, Investigational
IvacaftorThe serum concentration of Vinorelbine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Vinorelbine.Approved, Vet Approved
JosamycinThe serum concentration of Vinorelbine can be increased when it is combined with Josamycin.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Vinorelbine.Approved
KetoconazoleThe metabolism of Vinorelbine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Vinorelbine can be increased when it is combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Vinorelbine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Vinorelbine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Vinorelbine.Experimental
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Vinorelbine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Vinorelbine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Vinorelbine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Vinorelbine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Vinorelbine.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Vinorelbine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Vinorelbine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Vinorelbine.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Vinorelbine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Vinorelbine.Approved
LopinavirThe metabolism of Vinorelbine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Vinorelbine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Vinorelbine.Approved
LovastatinThe metabolism of Vinorelbine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Vinorelbine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Vinorelbine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Vinorelbine can be decreased when combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Vinorelbine.Illicit, Withdrawn
ManidipineThe metabolism of Vinorelbine can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Vinorelbine.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Vinorelbine.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Vinorelbine.Experimental
MethadoneThe metabolism of Vinorelbine can be decreased when combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Vinorelbine.Approved
MethotrimeprazineThe metabolism of Vinorelbine can be decreased when combined with Methotrimeprazine.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinorelbine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Vinorelbine.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Vinorelbine.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Vinorelbine.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Vinorelbine.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Vinorelbine.Approved, Illicit
MidostaurinThe metabolism of Vinorelbine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Vinorelbine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Vinorelbine.Approved
MitomycinThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Mitomycin.Approved
MitotaneThe serum concentration of Vinorelbine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Vinorelbine.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Vinorelbine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Vinorelbine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Vinorelbine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vinorelbine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Vinorelbine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Vinorelbine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Vinorelbine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Vinorelbine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Vinorelbine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Vinorelbine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Vinorelbine.Approved
NilotinibThe metabolism of Vinorelbine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Vinorelbine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Vinorelbine.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Vinorelbine.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Vinorelbine.Approved, Investigational
OlaparibThe metabolism of Vinorelbine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Vinorelbine can be increased when it is combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Vinorelbine.Experimental
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Vinorelbine.Approved
OsimertinibThe serum concentration of Vinorelbine can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Vinorelbine.Approved
PaclitaxelPaclitaxel may increase the neurotoxic activities of Vinorelbine.Approved, Vet Approved
PalbociclibThe serum concentration of Vinorelbine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Vinorelbine can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Vinorelbine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vinorelbine.Approved
Peginterferon alfa-2bThe serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Vinorelbine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Vinorelbine.Approved, Vet Approved, Withdrawn
PeruvosidePeruvoside may decrease the cardiotoxic activities of Vinorelbine.Experimental
PhenobarbitalThe metabolism of Vinorelbine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Vinorelbine can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Vinorelbine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinorelbine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Vinorelbine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Vinorelbine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Vinorelbine.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vinorelbine.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Vinorelbine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Vinorelbine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
PrimidoneThe metabolism of Vinorelbine can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Vinorelbine.Approved, Vet Approved
PromazineThe metabolism of Vinorelbine can be decreased when combined with Promazine.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Vinorelbine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Vinorelbine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vinorelbine.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Vinorelbine.Approved
QuinidineThe metabolism of Vinorelbine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Vinorelbine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vinorelbine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Vinorelbine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Vinorelbine.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Vinorelbine.Approved
RifabutinThe metabolism of Vinorelbine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Vinorelbine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Vinorelbine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vinorelbine.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Vinorelbine.Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Vinorelbine.Approved, Investigational
RitonavirThe metabolism of Vinorelbine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Vinorelbine.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Vinorelbine.Approved
RolapitantThe metabolism of Vinorelbine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Vinorelbine.Approved, Investigational
RopiniroleThe metabolism of Vinorelbine can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Vinorelbine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Vinorelbine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Vinorelbine.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Vinorelbine.Approved, Vet Approved
SaquinavirThe metabolism of Vinorelbine can be decreased when combined with Saquinavir.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Vinorelbine.Approved
SertralineThe metabolism of Vinorelbine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Vinorelbine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vinorelbine.Approved
SiltuximabThe serum concentration of Vinorelbine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vinorelbine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Vinorelbine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinorelbine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Vinorelbine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Vinorelbine.Approved
SolithromycinThe serum concentration of Vinorelbine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Vinorelbine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Vinorelbine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Vinorelbine.Experimental
SpiramycinThe serum concentration of Vinorelbine can be increased when it is combined with Spiramycin.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Vinorelbine.Investigational
St. John's WortThe serum concentration of Vinorelbine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Vinorelbine can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Vinorelbine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinorelbine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Vinorelbine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Vinorelbine.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Vinorelbine.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Vinorelbine.Approved
TelaprevirThe metabolism of Vinorelbine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Vinorelbine can be decreased when combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Vinorelbine.Approved
TerbinafineThe metabolism of Vinorelbine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Vinorelbine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Vinorelbine.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Vinorelbine.Withdrawn
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Vinorelbine.Approved
TiclopidineThe metabolism of Vinorelbine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Vinorelbine.Approved
TipranavirThe metabolism of Vinorelbine can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Vinorelbine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibVinorelbine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Vinorelbine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vinorelbine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Vinorelbine.Approved, Investigational
TranylcypromineThe metabolism of Vinorelbine can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vinorelbine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Vinorelbine.Approved
TylosinThe serum concentration of Vinorelbine can be increased when it is combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Vinorelbine.Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Vinorelbine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Vinorelbine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Vinorelbine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Vinorelbine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Vinorelbine.Approved
VenlafaxineThe metabolism of Vinorelbine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Vinorelbine can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Vinorelbine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Vinorelbine.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vinorelbine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Vinorelbine.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Vinorelbine.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Vinorelbine.Approved
ZiprasidoneThe metabolism of Vinorelbine can be decreased when combined with Ziprasidone.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Vinorelbine.Approved
Food Interactions
Not Available

References

General References
  1. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001 Nov;12(11):1643-9. [PubMed:11822766]
External Links
Human Metabolome Database
HMDB14505
KEGG Drug
D08680
PubChem Compound
44424639
PubChem Substance
46507772
ChemSpider
23284827
ChEBI
480999
ChEMBL
CHEMBL607994
Therapeutic Targets Database
DAP000765
PharmGKB
PA451881
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vinorelbine
ATC Codes
L01CA04 — Vinorelbine
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (102 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceCancer, Breast1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1CompletedTreatmentAdvanced Neoplasm1
1CompletedTreatmentBladder Cancers / Cervical Cancers / Endometrial Cancers / Vaginal Cancers1
1CompletedTreatmentCancer, Breast4
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Cancers / Lung Cancers1
1CompletedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Hereditary Breast/Ovarian Cancer - BRCA1 / Hereditary Breast/Ovarian Cancer - BRCA2 / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Hereditary Paraganglioma / Male Breast Cancer / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Pheochromocytoma / Pancreatic Polypeptide Tumor / Paraganglion neoplasm malignant / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Endometrial Carcinoma / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Neuroendocrine Carcinoma of the Skin / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pheochromocytoma / Recurrent Prostate Cancer / Recurrent Renal Cell Cancer / Recurrent Small Cell Lung Cancer / Recurrent Uterine Sarcoma / Regional Gastrointestinal Carcinoid Tumor / Regional Pheochromocytoma / Stage III Cervical Cancer / Stage III Endometrial Carcinoma / Stage III Neuroendocrine Carcinoma of the Skin / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage III Prostate Cancer / Stage III Renal Cell Cancer / Stage III Uterine Sarcoma / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Endometrial Carcinoma / Stage IV Neuroendocrine Carcinoma of the Skin / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Prostate Cancer / Stage IV Renal Cell Cancer / Stage IV Uterine Sarcoma / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Pleural Mesothelioma (MPM)1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentFailure or Contraindication of Trastuzumab Therapy / First or Second Line Therapy / HER2 Positive / Metastatic Breast Cancer (MBC)1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentMalignant Solid Tumours1
1TerminatedTreatmentMetastatic Breast Cancer (MBC) / Metastatic Non Small Cell Lung Cancer1
1Unknown StatusTreatmentLung Cancers1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentNonhematologic Malignancies1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdvanced Malignant Solid Tumors / Cancer, Breast1
1, 2Active Not RecruitingTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2CompletedTreatmentBreast / Cancers1
1, 2CompletedTreatmentCancer, Breast3
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMetastatic Cancers1
1, 2CompletedTreatmentProstate Cancer1
1, 2RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentStage IV (Metastatic) Breast Cancer1
1, 2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)2
2Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB1
2Active Not RecruitingTreatmentCancer, Breast3
2Active Not RecruitingTreatmentHER-2 Positive Breast Cancer1
2Active Not RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Tumor of the Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentMesothelioma1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)2
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Lymphocyte Predominant Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Sarcomas1
2CompletedTreatmentBreast Cancer Metastatic1
2CompletedTreatmentCancer of the Lung / Carcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2CompletedTreatmentCancer, Breast14
2CompletedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Prostate Cancer1
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCancers2
2CompletedTreatmentCervical Cancers1
2CompletedTreatmentConcomitant Radiochemotherapy / NSCLC Stage IIIB1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentHer2-negative Locally Advanced Breast Cancer / Her2-negative Metastatic Breast Cancer1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentLow-Grade Gliomas1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)11
2CompletedTreatmentLung Cancers8
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMetastatic Breast Cancer (MBC)4
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
2CompletedTreatmentNeoplasms, Breast2
2CompletedTreatmentNeoplasms, Lung1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (CD20+)1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentAggressive Non-Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentNon-small Cell Lung Cancer Stage Ⅱ / Non-small Cell Lung Cancer Stage ⅢA1
2RecruitingTreatmentAdvanced Stage IIIB / High Thymidylate Synthase Expression / Lung Cancer Non-Small Cell Cancer (NSCLC) / Secondary1
2RecruitingTreatmentAdvanced Triple-Negative Breast Cancer1
2RecruitingTreatmentAmyloidosis / Multiple Myeloma (MM)1
2RecruitingTreatmentCancer, Breast2
2RecruitingTreatmentEffects of Chemotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentLung neoplasm malignant1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)4
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Head and Neck1
2RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2RecruitingTreatmentSquamous Cell Esophageal Carcinoma1
2SuspendedTreatmentLow-Grade Gliomas1
2TerminatedTreatmentCancer, Breast7
2TerminatedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2TerminatedTreatmentMesothelioma1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentNeoplasms, Breast2
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusSupportive CareChemotherapeutic Agent Toxicity / Lung Cancers / Musculoskeletal Complications / Tiredness1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentCancer, Breast / Stage II Breast Cancer / Stage III Breast Cancer1
2Unknown StatusTreatmentEwing's Tumor / Medulloblastomas / Neoplasms, Connective and Soft Tissue / Neuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2Unknown StatusTreatmentLung Cancers3
2Unknown StatusTreatmentLymphoma, Hodgkins1
2Unknown StatusTreatmentMesothelioma1
2Unknown StatusTreatmentMesothelioma, Malignant2
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
2Unknown StatusTreatmentProstate Cancer1
2Unknown StatusTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentNeoplasms, Breast1
2WithdrawnTreatmentProstate Cancer1
2, 3CompletedTreatmentLung Cancers1
2, 3TerminatedTreatmentCancer, Breast1
2, 3TerminatedTreatmentCancer, Breast / HER2 Positive Breast Cancers1
2, 3TerminatedTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentCancer of Breast / Cancer, Breast / HER2-Negative Breast Cancer / Triple Negative Breast Cancer (TNBC) / Tumors, Breast1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3Active Not RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
3Active Not RecruitingTreatmentNeoplasms, Breast1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3CompletedPreventionCancers1
3CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
3CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
3CompletedTreatmentCancer, Breast2
3CompletedTreatmentCancer, Breast / Stage IV Breast Cancer1
3CompletedTreatmentHER2/Neu Over-expressing Locally Advanced Breast Cancer / Metastatic Breast Cancer (MBC)1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
3CompletedTreatmentLung Cancers7
3CompletedTreatmentMesothelioma, Malignant1
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3Not Yet RecruitingTreatment2-year Disease-Free Survival1
3Not Yet RecruitingTreatmentCancer, Breast1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Hydrothorax1
3Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3Not Yet RecruitingTreatmentPleural Mesothelioma Malignant Advanced1
3RecruitingTreatmentBreast Cancer Model / Cancer, Breast / Effects of Chemotherapy1
3RecruitingTreatmentCancer, Breast2
3RecruitingTreatmentCancer, Breast / Metastasis1
3RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Esophagus / Squamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentHER-2 Positive Breast Cancer / Neoplasms, Metastatic1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3TerminatedNot AvailableStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
3TerminatedTreatmentMalignant Lymphomas1
3Unknown StatusTreatmentCancer, Breast1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentLung Cancers4
3Unknown StatusTreatmentSarcomas1
3WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3WithdrawnTreatmentLung Cancers1
4Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
4CompletedTreatmentCancer, Breast1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
4Not Yet RecruitingTreatmentPrimary Breast Cancer1
Not AvailableAvailableNot AvailableMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation / Triple-Negative Breast Cancer (TNBC)1
Not AvailableCompletedNot AvailableCancer, Breast / Metastatic Cancers1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableRecruitingNot AvailableCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableTerminatedNot AvailableCancer, Breast1

Pharmacoeconomics

Manufacturers
  • Pierre fabre medicament
  • Actavis totowa llc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Ebewe pharma ges mbh nfg kg
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous10 mg/mL
Injection, solution, concentrateIntravenous10 mg/mL
Injection, solution, concentrateIntravenous50 mg/5mL
Injection, solutionIntravenous10 mg/mL
SolutionIntravenous10 mg
Prices
Unit descriptionCostUnit
Navelbine 50 mg/5 ml vial42.0USD ml
Vinorelbine 50 mg/5 ml vial27.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP4.39ALOGPS
logP4.65ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.87ChemAxon
pKa (Strongest Basic)8.72ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area133.87 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity216.99 m3·mol-1ChemAxon
Polarizability84.7 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.974
Blood Brain Barrier-0.8815
Caco-2 permeable+0.5602
P-glycoprotein substrateSubstrate0.9283
P-glycoprotein inhibitor IInhibitor0.7488
P-glycoprotein inhibitor IIInhibitor0.7388
Renal organic cation transporterNon-inhibitor0.6979
CYP450 2C9 substrateNon-substrate0.8513
CYP450 2D6 substrateSubstrate0.6471
CYP450 3A4 substrateSubstrate0.7247
CYP450 1A2 substrateNon-inhibitor0.8415
CYP450 2C9 inhibitorNon-inhibitor0.7863
CYP450 2D6 inhibitorNon-inhibitor0.8369
CYP450 2C19 inhibitorNon-inhibitor0.8381
CYP450 3A4 inhibitorNon-inhibitor0.8095
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6672
Ames testNon AMES toxic0.8064
CarcinogenicityNon-carcinogens0.9299
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8350 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9014
hERG inhibition (predictor II)Non-inhibitor0.5171
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Vinca alkaloids
Sub Class
Not Available
Direct Parent
Vinca alkaloids
Alternative Parents
Ibogan-type alkaloids / Carbazoles / 3-alkylindoles / Tricarboxylic acids and derivatives / Dialkylarylamines / Anisoles / Alkyl aryl ethers / Aralkylamines / N-alkylpyrrolidines / Tertiary alcohols
show 11 more
Substituents
Vinca alkaloid skeleton / Catharanthine skeleton / Carbazole / 3-alkylindole / Indole / Indole or derivatives / Tricarboxylic acid or derivatives / Anisole / Tertiary aliphatic/aromatic amine / Dialkylarylamine
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBB
Uniprot ID
P07437
Uniprot Name
Tubulin beta chain
Molecular Weight
49670.515 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635-48. [PubMed:9515574]
  4. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 5):66-70; discussion 70-1. [PubMed:7740336]
  5. Seve P, Dumontet C: [Class III beta tubulin expression in nonsmall cell lung cancer]. Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25. [PubMed:20403547]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:22